Welcome to the Cellebrite Q3 2024 Financial Results Conference Call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for your questions following the presentation. If you would like to ask a question at that time, please press star one on your telephone keypad. If at any point your question has been answered, you may remove yourself from the queue by pressing star two. So others can hear your questions clearly, we ask that you pick up your handset for best sound quality. Lastly, if you should require operator assistance, please press star zero. I would now like to turn the call over to your first speaker today, Mr. Andrew Cramer. Mr. Cramer, the floor is yours.
Thank you, Todd, and welcome everybody to Cellebrite Q3 2024 Financial Results Call. I'm joined in New York City today by Yossi Carmil, Cellebrite CEO; Dana Gerner, Cellebrite CFO; and Tom Hogan, Cellebrite's Executive Chairman. There is a slide presentation that accompanies our prepared remarks. Please advance the slides in the webcast viewer to follow our commentary. We will call out the slide number we are referring to in our remarks. The call is being recorded, and a replay of the call will be made available on our website shortly after the call, along with a transcript of this event soon after.
Starting with Slide 2 , a copy of today's press release and financial statements, including GAAP to non-GAAP reconciliations, the slide presentation, and the quarterly financial tables and supplemental historical information for the first three quarters of 2024 and each quarter of 2023 and 2022, are available on the Investor Relations website at investors.cellebrite.com. Unless stated otherwise, our discussion of our Q3 2024 financial metrics, as well as the financial metrics provided in our outlook, will be done on a non-GAAP basis only, and all historical comparisons are with the Q3 of 2023. In addition, please note that statements made during this call that are not statements of historical facts constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward-looking statements not to occur.
They could also cause actual results to differ materially from historical results and/or from forecasts. Some of these forward-looking statements are discussed under the heading Risk Factors and elsewhere in the Company's Annual Report on Form 20-F, filed with the SEC on March 21, 2024, and as amended on April 12, 2024. The Company does not undertake to update any forward-looking statements to reflect future events or circumstances. Slide 3 provides the agenda of topics we'll cover on today's call, and with that being said, I'll turn the call over to Yossi Carmil, Cellebrite CEO. Yossi?
Thank you, Andy, and thank you all for joining us this morning. So we delivered a strong Q1 performance that exceeded expectations thanks to increasing traction with our case-to-closure platform, what we call the C2C platform, the impact of our ongoing investment in market-leading innovation, and solid execution on all fronts. As illustrated on Slide 4, we produced notable ARR growth, surpassed $100 million in quarterly revenue for the first time in the company's history, and generated outstanding profitability. We are proud that we have consistently delivered a healthy mix of ARR growth and profitability, with recent results comfortably exceeding our baseline for the rule of 45 performance. So put it simply, Cellebrite's business momentum remained strong in the Q3, and we anticipate a positive finish to our year. Now, Dana will cover this in a few minutes.
Beyond the solid quarterly results, we took important strategic actions and accomplishments over the past several months, all of which are architected to drive long-term profitable growth and corresponding enterprise value. Cellebrite is uniquely positioned as a differentiated end-to-end platform provider with software offerings spanning the digital investigative lifecycle. Our AI-driven C2C platform enables customers to close more cases faster by elevating their productivity and efficiency for collecting, reviewing, sharing, and analyzing digital evidence. We have taken deliberate steps to anchor our C2C platform around three increasingly integrated flagship software solutions, and I want to give here a brief overview. So Insights is our family of digital forensic software that enables law enforcement to collect and review digital evidence from mobile phones, cloud applications, computers, and many other digital witnesses.
Guardian is our set of SaaS-based case and evidence management offerings for managing the examination process, securely sharing evidence, and enabling inter-agency and cross-agency collaboration. Our Pathfinder investigative suite includes AI-powered analytics and open-source intelligence tools for expediting investigations by surfacing leads, pinpointing connections, and identifying valuable evidence buried within mountains of structured and unstructured data across multiple digital witnesses. So we are mobilizing to capitalize on the extensive opportunities we see to expand our customer spending with us while also winning new logos. To that end, Cellebrite Federal Solutions was launched earlier this summer to expand our relationship with the U.S. federal government, and this unit is now fully operational. And I'm pleased to share that we delivered an excellent Q3 in the U.S. federal sector.
In addition, we have continued to augment our quota-carrying sales force in all major geographies to amplify our go-to-market motion for upgrades, upsells, and cross-sells. As we look forward towards 2025, this investment positions Cellebrite with the ramped sales capacity which is required for sustaining solid top-line expansion and extending to new buying centers within our installed customer base. Cellebrite's relationship with over 5,300 public sector customers typically begins by helping examiners and investigators to collect and review digital evidence across mobile phones, computers, cloud, and other digital witnesses. There is a long, broad growth runway ahead for Cellebrite Digital Forensic Solutions, and part of this expansion is expected to come from upgrading customers from our legacy digital forensic software to our new Insights suite. The value proposition for this upgrade is compelling.
Insights leverages a modern tech stack along with both proven and new digital forensic capabilities that enable customers to complete an examination as much as twice as fast while accessing more devices, extracting more data, and revealing more important information. In addition to the Insights upgrade, we believe our customers will want to expand the scope of their deployments, whether it is in a traditional technical lab environment or by extending our technology into the field. Just as important, we see substantial opportunity for customers to leverage our modular approach to Insights by adding high-value capabilities around advanced local access or unlocks and for automating and accelerating key examination processes. When we launched Insights earlier this year, our goal was to operate the vast majority of our installed base over the next three years with 10% adoption in 2024.